Adjuvant chemotherapy for non-small cell lung cancer

Tatsuro Okamoto, Yukito Ichinose

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has been reported to be effective for patients with postoperative stage I to IIIA NSCLC in western countries. On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan. We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC.

Original languageEnglish
Pages (from-to)1985-1990
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number13
Publication statusPublished - Jan 1 2006

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant chemotherapy for non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this